94 related articles for article (PubMed ID: 9661637)
1. Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells.
Blagosklonny MV; Giannakakou P; Wojtowicz M; Romanova LY; Ain KB; Bates SE; Fojo T
J Clin Endocrinol Metab; 1998 Jul; 83(7):2516-22. PubMed ID: 9661637
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus-mediated tumor suppressor p53 gene therapy for anaplastic thyroid carcinoma in vitro and in vivo.
Nagayama Y; Yokoi H; Takeda K; Hasegawa M; Nishihara E; Namba H; Yamashita S; Niwa M
J Clin Endocrinol Metab; 2000 Nov; 85(11):4081-6. PubMed ID: 11095436
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic usefulness of wild-type p53 gene introduction in a p53-null anaplastic thyroid carcinoma cell line.
Narimatsu M; Nagayama Y; Akino K; Yasuda M; Yamamoto T; Yang TT; Ohtsuru A; Namba H; Yamashita S; Ayabe H; Niwa M
J Clin Endocrinol Metab; 1998 Oct; 83(10):3668-72. PubMed ID: 9768682
[TBL] [Abstract][Full Text] [Related]
4. Establishment of anaplastic thyroid carcinoma cell lines useful for analysis of chemosensitivity and carcinogenesis.
Asakawa H; Kobayashi T; Komoike Y; Yanagawa T; Takahashi M; Wakasugi E; Maruyama H; Tamaki Y; Matsuzawa Y; Monden M
J Clin Endocrinol Metab; 1996 Oct; 81(10):3547-52. PubMed ID: 8855799
[TBL] [Abstract][Full Text] [Related]
5. In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug.
Blagosklonny MV; el-Deiry WS
Int J Cancer; 1996 Jul; 67(3):386-92. PubMed ID: 8707413
[TBL] [Abstract][Full Text] [Related]
6. Gal-3 is stimulated by gain-of-function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas.
Lavra L; Ulivieri A; Rinaldo C; Dominici R; Volante M; Luciani E; Bartolazzi A; Frasca F; Soddu S; Sciacchitano S
J Pathol; 2009 May; 218(1):66-75. PubMed ID: 19199318
[TBL] [Abstract][Full Text] [Related]
7. Endogenous p21WAF1/CIP1 status predicts the response of human tumor cells to wild-type p53 and p21WAF1/CIP1 overexpression.
Kralj M; Husnjak K; Körbler T; Pavelić J
Cancer Gene Ther; 2003 Jun; 10(6):457-67. PubMed ID: 12768191
[TBL] [Abstract][Full Text] [Related]
8. p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells.
Moretti F; Farsetti A; Soddu S; Misiti S; Crescenzi M; Filetti S; Andreoli M; Sacchi A; Pontecorvi A
Oncogene; 1997 Feb; 14(6):729-40. PubMed ID: 9038381
[TBL] [Abstract][Full Text] [Related]
9. The histone deacetylase inhibitor FR901228 (desipeptide) restores expression and function of pseudo-null p53.
Kitazono M; Bates S; Fok P; Fojo T; Blagosklonny MV
Cancer Biol Ther; 2002; 1(6):665-8. PubMed ID: 12642691
[TBL] [Abstract][Full Text] [Related]
10. Adenovirus-mediated p53 gene therapy reverses resistance of breast cancer cells to adriamycin.
Qi X; Chang Z; Song J; Gao G; Shen Z
Anticancer Drugs; 2011 Jul; 22(6):556-62. PubMed ID: 21637162
[TBL] [Abstract][Full Text] [Related]
11. A single recombinant adenovirus expressing p53 and p21-targeting artificial microRNAs efficiently induces apoptosis in human cancer cells.
Idogawa M; Sasaki Y; Suzuki H; Mita H; Imai K; Shinomura Y; Tokino T
Clin Cancer Res; 2009 Jun; 15(11):3725-32. PubMed ID: 19458054
[TBL] [Abstract][Full Text] [Related]
12. Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer.
Gurnani M; Lipari P; Dell J; Shi B; Nielsen LL
Cancer Chemother Pharmacol; 1999; 44(2):143-51. PubMed ID: 10412949
[TBL] [Abstract][Full Text] [Related]
13. ONYX-015, an E1B gene-defective adenovirus, induces cell death in human anaplastic thyroid carcinoma cell lines.
Portella G; Scala S; Vitagliano D; Vecchio G; Fusco A
J Clin Endocrinol Metab; 2002 Jun; 87(6):2525-31. PubMed ID: 12050209
[TBL] [Abstract][Full Text] [Related]
14. p53/p21(CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin.
Huang S; Liu LN; Hosoi H; Dilling MB; Shikata T; Houghton PJ
Cancer Res; 2001 Apr; 61(8):3373-81. PubMed ID: 11309295
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.
Wen SF; Xie L; McDonald M; DiGiacomo R; Chang A; Gurnani M; Shi B; Liu S; Indelicato SR; Hutchins B; Nielsen LL
Cancer Gene Ther; 2000 Nov; 7(11):1469-80. PubMed ID: 11129289
[TBL] [Abstract][Full Text] [Related]
16. Apoptosis induced by adenovirus-mediated p53 gene transfer in human glioma correlates with site-specific phosphorylation.
Shono T; Tofilon PJ; Schaefer TS; Parikh D; Liu TJ; Lang FF
Cancer Res; 2002 Feb; 62(4):1069-76. PubMed ID: 11861384
[TBL] [Abstract][Full Text] [Related]
17. Differential chemosensitivity of breast cancer cells to ganciclovir treatment following adenovirus-mediated herpes simplex virus thymidine kinase gene transfer.
Li PX; Ngo D; Brade AM; Klamut HJ
Cancer Gene Ther; 1999; 6(2):179-90. PubMed ID: 10195885
[TBL] [Abstract][Full Text] [Related]
18. Differential activation of the Fas/CD95 pathway by Ad-p53 in human gliomas.
Cerrato JA; Khan T; Koul D; Lang FF; Conrad CA; Yung WK; Liu TJ
Int J Oncol; 2004 Feb; 24(2):409-17. PubMed ID: 14719118
[TBL] [Abstract][Full Text] [Related]
19. Acute overexpression of wt p53 facilitates anticancer drug-induced death of cancer and normal cells.
Blagosklonny MV; El-Deiry WS
Int J Cancer; 1998 Mar; 75(6):933-40. PubMed ID: 9506540
[TBL] [Abstract][Full Text] [Related]
20. Selective activity of BS-RNase against anaplastic thyroid cancer.
Kotchetkov R; Cinatl J; Krivtchik AA; Vogel JU; Matousek J; Pouckova P; Kornhuber B; Schwabe D; Cinatl J
Anticancer Res; 2001; 21(2A):1035-42. PubMed ID: 11396137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
